Protocol for the Stimulating β 3 -Adrenergic Receptors for Peripheral Artery Disease (STAR-PAD) trial: a double-blinded, randomised, placebo-controlled study evaluating the effects of mirabegron on functional performance in patients with peripheral arterial disease
Open Access
Abstract
Introduction: There is currently only one approved medication effective at improving walking distance in people with intermittent claudication. Preclinical data suggest that the β 3 -adrenergic receptor agonist (mirabegron) could be repurposed to treat intermittent claudication associated with peripheral artery disease. The aim of the Stimulating β 3 -Adrenergic Receptors for Peripheral Artery Disease (STAR-PAD) trial is to test whether mirabegron improves walking distance in people with intermittent claudication. Methods and analysis: The STAR-PAD trial is a Phase II, multicentre, double-blind, randomised, placebo-controlled trial of mirabegron versus placebo on walking distance in patients with PAD. A total of 120 patients aged ≥40 years with stable PAD and intermittent claudication will be randomly assigned (1:1 ratio) to receive either mirabegron (50 mg orally once a day) or matched placebo, for 12 weeks. The primary endpoint is change in peak walking distance as assessed by a graded treadmill test. Secondary endpoints will include: (i) initial claudication distance; (ii) average daily step count and total step count and (iii) functional status and quality of life assessment. Mechanistic substudies will examine potential effects of mirabegron on vascular function, including brachial artery flow-mediate dilatation; MRI assessment of lower limb blood flow, tissue perfusion and arterial stiffness and numbers and angiogenesis potential of endothelial progenitor cells. Given that mirabegron is safe and clinically available for alternative purposes, a positive study is positioned to immediately impact patient care. Ethics and dissemination: The STAR-PAD trial is approved by the Northern Sydney Local Health District Human Research Ethics Committee (HREC/18/HAWKE/50). The study results will be published in peer-reviewed medical or scientific journals and presented at scientific meetings, regardless of the study outcomes. Trial registration number: ACTRN12619000423112; Results.Keywords
Funding Information
- Heart Foundation (101687)
This publication has 34 references indexed in Scilit:
- Association between large detectable clonal mosaicism and type 2 diabetes with vascular complicationsNature Genetics, 2013
- ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries * The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC)European Heart Journal, 2011
- One-Year Costs in Patients With a History of or at Risk for Atherothrombosis in the United StatesCirculation: Cardiovascular Quality and Outcomes, 2008
- Ethnic-Specific Prevalence of Peripheral Arterial Disease in the United StatesAmerican Journal of Preventive Medicine, 2007
- Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)Journal of Vascular Surgery, 2007
- Guidelines for Noninvasive Vascular Laboratory Testing: A Report from the American Society of Echocardiography and the Society of Vascular Medicine and BiologyJournal of the American Society of Echocardiography, 2006
- Endothelial β 3 -Adrenoceptors Mediate Vasorelaxation of Human Coronary Microarteries Through Nitric Oxide and Endothelium-Dependent HyperpolarizationCirculation, 2004
- The intermittent claudication questionnaire: A patient-assessed condition-specific health outcome measureJournal of Vascular Surgery, 2002
- Trans-Atlantic Conference on Clinical Trial Guidelines in PAOD (Peripheral Arterial Occlusive Disease) Clinical Trial MethodologyEuropean Journal of Vascular and Endovascular Surgery, 1999
- Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosisThe Lancet, 1992